France-US Crossed-Views Life Sciences Growth and Investment Strategies

DLA Piper France
27 rue Laffitte
75009 Paris

Exploiting opportunities in both France and the US is a strategic challenge for life science companies and investors. What are the key challenges of raising funds from French and American investors (both raising private capital and IPOs on Euronext/Nasdaq)? On both sides of the Atlantic, what are the current licensing and M&A trends? How to anticipate the impact of new regulations on AI, data protection and health products in Europe and the US?

We are pleased to invite you to join our Life Sciences team and France Biotech on 22 May 2025 for an engaging afternoon of discussion and networking at our Paris office, bringing together key players from across the Life Sciences ecosystem.

You will benefit from the insights of our US partners and renowned industry experts across pharmaceuticals, medical devices, biotechnology, investment, and healthcare regulation. The event will conclude with a lively networking cocktail, providing a valuable opportunity to network, share ideas and stay ahead.

14:30    Welcome and Registration

 

15:00    Introduction 

• Sonia de Kondserovsky (Partner, Head of Life Sciences, DLA Piper France),
• Frédéric Girard (President, France Biotech).

 

15:10    Panel 1: Raising capital in France and in the US (private capital, IPOs and royalty financing)

• Raising private capital,
• Royalty financing,
• Raising capital on the financial markets (double listings Euronext/Nasdaq).

Moderator: Victoria Rhodes (Partner, Head of Corporate Life Sciences UK, DLA Piper UK).

DLA Piper speakers:

• Joshua Kaufman (Co-Chair Capital Markets, DLA Piper US) – Listings and dual listings,
• Shehzad Huda (Emerging Growth and Venture Capital, DLA Piper US) – Private capital raisings.

External experts:

• Pascal Prigent (CEO, Genfit),
• Vincent Meunier (Healthcare Investment Banking MD, Bryan Garnier part of the US Stifel group, subject to regulatory approval),
• Elisa El Nouchi (Senior Associate in the Life Sciences Investment team, Bpifrance). 
• Jean-François Rivassou (Partner, Kurma Partners part of the Eurazeo group).

 

16:00    Coffee break

 

16:30    Panel 2: Licensing and M&A trends

• Comparing ecosystems and market dynamics,
• Strategic tips for licensing and M&A.

Moderator: Sonia de Kondserovsky (Partner, Head of Life Sciences, DLA Piper France).

DLA Piper speakers:

• Lauren Murdza (Co-Chair Life Sciences Licensing and Commercial Transactions, DLA Piper US).

External experts:

• Philippe Lopes Fernandes (Executive Vice President, Chief Business Officer, Ipsen),
• Frédéric Scaerou (Head of Global Business Development, Servier),
• Michael Stewart (Global Head of Legal Transactions, Sanofi),
• Robert Rozemulder (Managing Director, Rothschild & Co).

 

17:15    Panel 3: Solving the regulatory puzzle: AI, Data, and Product Regulations

• Navigating the increasingly complex regulatory landscape,
• Impact of the latest reforms,
• Key take-aways from experts and industry players.

Moderator: Marco de Morpurgo (Partner, Global Co-Chair, Life Sciences Sector, DLA Piper Europe).

DLA Piper speakers:  

• John McKinlay (Head of Intellectual Property and Technology Practice, DLA Piper UK),
• Marion Abecassis (Senior Associate, Life Sciences & Regulatory, DLA Piper France).

External experts: 

• David Del Bourgo (CEO and Co-founder, WhiteLab Genomics - Leader of the TechBio initiative at France Biotech),
• Simon Turner (Partner in Digital Medicine strategy, Sofinnova),
• Laure Millet (Corporate Development Lead, Implicity).

 

18:00    Cocktail